As part of our ongoing aim to bring you reports of innovative developments, we have added a review of the recent QUAZAR AML-001 trial which recorded the efficacy and safety of oral azacitidine as maintenance therapy for older patients with AML who were in first remission after intensive chemotherapy.
Independent commentary is provided by Associate Professor Ashish Bajel, a haematologist and BMT physician at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)